A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.

Phase 2

Completed

• Conditions: Age-Related Macular Degeneration

• Registration Number: NCT00321997
• Lead Sponsor: Eyetech Pharmaceuticals

Brief Summary

The purpose of this study is to compare the ability of different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or impriving vision in patients with wet AMD when compared to placebo injections.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-05
• Status Verified: 2006-05
• Study First Submitted: 2006-05-02
• Study First Submitted QC: 2006-05-02
• Last Update Submitted: 2006-05-02
• Study First Posted: 2006-05-04
• Last Update Posted: 2006-05-04
• Study Completion: 2007-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 540

Inclusion Criteria

Subjects of either gender, aged 50 years or greater. Subfoveal choroidal neovascularization (CNV) due to AMD. Best corrected visual acuity in the study eye between 20/40 and 20/320.

Exclusion Criteria

Any prior subfoveal thermal laser therapy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL